clinical trial · NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)Aggressive Systemic Mastocytosis (ASM)bezuclastinib
brief summary
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
started
Nov 9, 2021
primary completion
Sep 19, 2025
completion
Jul 1, 2027
last updated
Apr 24, 2026
official title
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol